Algert Global’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Algert Global’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-33,430	Closed	-$37K	–	1355
2022 Q4	$37K	Hold	33,430	–	–	﹤0.01%	1106
2022 Q3	$78K	Hold	33,430	–	–	﹤0.01%	1120
2022 Q2	$101K	Buy	+33,430	New	+$163K	0.01%	1114
2021 Q4	–	Sell	-10,200	Closed	-$76K	–	1157
2021 Q3	$76K	Buy	+10,200	New	+$63.2K	0.01%	986
2020 Q3	–	Sell	-27,090	Closed	-$187K	–	507
2020 Q2	$187K	Sell	27,090 -13,320	-33%	-$71.8K	0.06%	335
2020 Q1	$192K	Buy	40,410 +15,100	+60%	+$86.9K	0.08%	305
2019 Q4	$221K	Hold	25,310	–	–	0.07%	303
2019 Q3	$84K	Sell	25,310 -4,050	-14%	-$16.2K	0.03%	334
2019 Q2	$145K	Buy	29,360 +15,178	+107%	+$80.6K	0.05%	303
2019 Q1	$88K	Buy	+14,182	New	+$68.5K	0.05%	281

Other funds holding JNCE

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

ACM

Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Algert Global's JNCE Position: Q1 2023 in Review

Algert Global sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 33,430 shares — an estimated $37K sold.

Algert Global first reported a position in JNCE in Q1 2019 and held it in 10 quarters. The position peaked at $221K in Q4 2019. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

Algert Global reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Algert Global sold 33,430 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $37K.
Algert Global first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2019 and held it in 10 quarters.
Algert Global's Jounce Therapeutics, Inc. Common Stock position peaked at $221K in Q4 2019.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Algert Global's 13F filing for Q1 2023, filed 12 May 2023.